These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY. Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005 [TBL] [Abstract][Full Text] [Related]
4. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident. Yamamoto S; Romanenko A; Wei M; Masuda C; Zaparin W; Vinnichenko W; Vozianov A; Lee CC; Morimura K; Wanibuchi H; Tada M; Fukushima S Cancer Res; 1999 Aug; 59(15):3606-9. PubMed ID: 10446970 [TBL] [Abstract][Full Text] [Related]
5. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. Miyake H; Hara I; Kamidono S; Eto H J Urol; 2004 Sep; 172(3):1127-9. PubMed ID: 15311055 [TBL] [Abstract][Full Text] [Related]
6. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Habuchi T; Takahashi R; Yamada H; Ogawa O; Kakehi Y; Ogura K; Hamazaki S; Toguchida J; Ishizaki K; Fujita J Cancer Res; 1993 Aug; 53(16):3795-9. PubMed ID: 8339293 [TBL] [Abstract][Full Text] [Related]
7. p53 gene mutations in human urothelial carcinomas: analysis by immunohistochemistry and single-strand conformation polymorphism. Oyasu R; Nan L; Szumel RC; Kawamata H; Hirohashi S Mod Pathol; 1995 Feb; 8(2):170-6. PubMed ID: 7777479 [TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of the p53 tumor suppressor gene using paraffin-embedded specimens of human transitional cell carcinomas by the direct sequencing method. Masuda A; Kikuchi YY; Kawamura N Tokai J Exp Clin Med; 2000 Jun; 25(2):69-77. PubMed ID: 11127510 [TBL] [Abstract][Full Text] [Related]
9. No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract. Stoehr R; Brinkmann A; Filbeck T; Gamper C; Wild P; Blaszyk H; Hofstaedter F; Knuechel R; Hartmann A Oncol Rep; 2004 Jan; 11(1):137-41. PubMed ID: 14654916 [TBL] [Abstract][Full Text] [Related]
10. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma. Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850 [TBL] [Abstract][Full Text] [Related]
11. Genetic evidence for the multicentric origin of synchronous multiple gastric carcinoma. Kang GH; Kim CJ; Kim WH; Kang YK; Kim HO; Kim YI Lab Invest; 1997 Mar; 76(3):407-17. PubMed ID: 9121123 [TBL] [Abstract][Full Text] [Related]
12. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726 [TBL] [Abstract][Full Text] [Related]
13. Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study. Dalbagni G; Ren ZP; Herr H; Cordon-Cardo C; Reuter V Clin Cancer Res; 2001 Sep; 7(9):2797-801. PubMed ID: 11555595 [TBL] [Abstract][Full Text] [Related]
14. Discordance of p53 mutations of synchronous colorectal carcinomas. Eguchi K; Yao T; Konomoto T; Hayashi K; Fujishima M; Tsuneyoshi M Mod Pathol; 2000 Feb; 13(2):131-9. PubMed ID: 10697269 [TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of p53 gene mutations in bladder tumors. Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295 [TBL] [Abstract][Full Text] [Related]
16. [The study of p53 gene mutation in human bladder cancer]. Ding Q; Zhang Y; Sun X Zhonghua Wai Ke Za Zhi; 1995 Nov; 33(11):684-6. PubMed ID: 8731915 [TBL] [Abstract][Full Text] [Related]
17. Frequent association of p53 gene mutation in invasive bladder cancer. Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947 [TBL] [Abstract][Full Text] [Related]
18. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Chung KY; Mukhopadhyay T; Kim J; Casson A; Ro JY; Goepfert H; Hong WK; Roth JA Cancer Res; 1993 Apr; 53(7):1676-83. PubMed ID: 8453641 [TBL] [Abstract][Full Text] [Related]
19. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449 [TBL] [Abstract][Full Text] [Related]
20. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]